Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time?
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada;
Michael J
MJ
Knauer
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Department of Clinical Biochemistry, University Health Network; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada; ediamandis@mtsinai.on.ca.
Eleftherios P
EP
Diamandis
Director of Pharmacogenomics & Personalized Therapeutics, Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai School, New York, NY;
Jean-Sebastien
JS
Hulot
Professor of Medicine, Physiology and Pharmacology, and Oncology, Wolfe Medical Research, Chair in Pharmacogenomics, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada;
Richard B
RB
Kim
Program Director, Adult Interventional Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Derek Y F
DY
So
D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics* / Q000378:metabolism; D016903:Drug Monitoring; D060005:Genotyping Techniques; D006801:Humans; D010597:Pharmacogenetics; D010975:Platelet Aggregation Inhibitors / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D011355:Prodrugs / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D011355:Prodrugs; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine